Beam Therapeutics Announces Portfolio Progress and Reports Third Quarter 2022 Financial Results

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. ABBV
3. META
4. SPY
5. IBM
6. MU
7. FDX
8. BLZE
9. NKE
10. PRIM

Go back to Beam Therapeutics Announces Portfolio Progress and Reports Third Quarter 2022 Financial Results

Beam Therapeutics Inc (BEAM) PT Lowered to $60 at RBC Capital

November 7, 2022 10:51 AM EST

RBC Capital analyst Luca Issi lowered the price target on Beam Therapeutics Inc (NASDAQ: BEAM) to $60.00 (from $76.00) while maintaining a Sector Perform rating.

The analyst comments "BEAM is prioritizing the lead HbF-boosting SCD program over the next-gen Makassar. We caught up... More

Beam Therapeutics Inc (BEAM) PT Lowered to $103 at Stifel

November 7, 2022 9:32 AM EST

Stifel analyst Benjamin Burnett lowered the price target on Beam Therapeutics Inc (NASDAQ: BEAM) to $103.00 (from $120.00) while maintaining a Buy rating.

The analyst comments "We are reiterating our Buy rating on BEAM following 3Q22 updates. Main pushbacks from bears have been on (potentially... More

Beam, Inc. (BEAM) Misses Q3 EPS by 28c, Revenues Beats

November 7, 2022 6:32 AM EST

Beam, Inc. (NASDAQ: BEAM) reported Q3 EPS of ($1.56), $0.28 worse than the analyst estimate of ($1.28). Revenue for the quarter came in at $15.8 million versus the consensus estimate of $7.15 million.

Ended Third Quarter 2022 with $1.1 Billion in Cash, Cash Equivalents and Marketable Securities.

For earnings... More